

## REMARKS

The Examiner has issued a Restriction Requirement, restricting the claims to one of five inventions:

- I. Claims 26-39 drawn to a method of treating a subject having a neoplastic disorder comprising administering an anti-caveolin antibody;
- II. Claims 35, 40-59, 66-85, and 98-104 drawn to a method of treating a subject having a neoplastic disorder comprising administering caveolin nucleic acid;
- III. Claims 60-64 drawn to a method of treating a disorder comprising administering a composition that suppresses caveolin expression in a neoplastic cell;
- IV. Claim 65 drawn to a therapeutic composition comprising an anti-caveolin agent; and
- V. Claims 86-97 and 105, drawn to a composition comprising an isolated nucleic acid and vectors that express a caveolin nucleic acid.

In response, Applicant elects Group I, claims 26-39, without traverse.

Applicant further elects from Species Group (a), the treatment of prostate cancer for prosecution on the merits. Currently, claims 26 and 35 are generic claims.


### Status of the Claims

Claims 1-25 have previously been canceled. Claims 26-105 are subject to a restriction requirement. In response, claims 40-105 have been canceled without prejudice or disclaimer as drawn to non-elected inventions. Applicant reserves the right to prosecute the subject matter of the canceled claims in this, or a related application.

Claims 32-34 have been amended to further clarify what Applicant regards as his invention. These amendments do not broaden the scope of the amended claims in any way.

Applicant respectfully submits that the pending claims are in condition for allowance, and solicit an early indication to that effect. Should the Examiner have any questions, comments or suggestions that would more quickly progress the claims to allowance, the Examiner is invited to contact the undersigned representative at 512.542.8446.

Respectfully submitted,



Timothy S. Corder  
Reg. No. 38,414  
Agent for Applicants

Vinson & Elkins L.L.P.  
First City Tower  
1001 Fannin  
Suite 2300  
Houston, Texas 77002-6760  
512.542.8446  
Date: February 14, 2007